04/29/2024 Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion Read more about Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
04/09/2024 Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum Read more about Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum
02/27/2024 Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences Read more about Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
02/27/2024 Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences Read more about Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
02/06/2024 Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results Read more about Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results
02/01/2024 Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024 Read more about Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024
02/01/2024 Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference Read more about Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
01/18/2024 Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium Read more about Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
01/08/2024 Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company Read more about Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company
01/05/2024 Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18 Read more about Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18
